NHS Framework Agreement-Branded Medicines - National Proprietary Pharmaceuticals
The value below is a framework or dynamic market ceiling: the maximum
that could be spent across all call-offs, not the value of a single contract.
Aggregate figures on this site exclude these to avoid double counting.
key details
| Value | £304,504,000 |
|---|---|
| Status | complete |
| Category (CPV) | 33600000 |
| Deadline | 12 Dec 2022 |
| Contract start | 1 May 2023 |
| Contract end | 30 Apr 2025 |
| Procedure | open |
| SME suitable | Yes |
| OCID | ocds-b5fd17-f3419ee6-884e-4ba4-9f88-cdfcb350ba4e |
Awards (50)
This procurement was awarded to 50 suppliers. Values shown are per-award; the notice total is £304,504,000.
| Supplier | Value | Date | Status |
|---|---|---|---|
| Accord-UK Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Aspen Pharmacare UK Limited shared | £304,504,000 | 23 Apr 2023 | active |
| Aspire Pharma Limited shared | £304,504,000 | 23 Apr 2023 | active |
| Astellas Pharma Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Aventis Pharma ltd t/a Sanofi shared | £304,504,000 | 23 Apr 2023 | active |
| Bayer Plc shared | £304,504,000 | 23 Apr 2023 | active |
| Chiesi Limited shared | £304,504,000 | 23 Apr 2023 | active |
| CST Pharma Limited shared | £304,504,000 | 23 Apr 2023 | active |
| Day Lewis Medical Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Dexcel Pharma Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Drugsrus Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Eli Lilly & Company Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Ferring Pharmaceuticals Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Gedeon Richter UK Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Gerot Lannach UK Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Glenmark Pharmaceuticals Europe Limited shared | £304,504,000 | 23 Apr 2023 | active |
| Ipsen shared | £304,504,000 | 23 Apr 2023 | active |
| Janssen-Cilag Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Kent Pharma Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Lupin Healthcare (UK) Limited shared | £304,504,000 | 23 Apr 2023 | active |
| Martindale Pharma shared | £304,504,000 | 23 Apr 2023 | active |
| medac Pharma LLP shared | £304,504,000 | 23 Apr 2023 | active |
| Merck Serono Limited shared | £304,504,000 | 23 Apr 2023 | active |
| Mercury Pharmaceuticals Limited shared | £304,504,000 | 23 Apr 2023 | active |
| Morningside Pharmaeuticals shared | £304,504,000 | 23 Apr 2023 | active |
| Mylan shared | £304,504,000 | 23 Apr 2023 | active |
| Napp Pharmaceuticals Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Neuraxpharm UK Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Nordic Pharma shared | £304,504,000 | 23 Apr 2023 | active |
| Norgine Pharmaceuticals Limited shared | £304,504,000 | 23 Apr 2023 | active |
| Novartis Pharmaceuticals UK Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Orifarm UK shared | £304,504,000 | 23 Apr 2023 | active |
| Otsuka Pharmaceuticals UK Limited shared | £304,504,000 | 23 Apr 2023 | active |
| Pfizer Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Pharmasure shared | £304,504,000 | 23 Apr 2023 | active |
| QDEM PHARMACEUTICALS LIMITED shared | £304,504,000 | 23 Apr 2023 | active |
| Recordati Rare Diseases UK Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Ridge Pharma shared | £304,504,000 | 23 Apr 2023 | active |
| ROVI Biotech Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Sandoz Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Selective Supplies Ltd. shared | £304,504,000 | 23 Apr 2023 | active |
| Synchrony shared | £304,504,000 | 23 Apr 2023 | active |
| Takeda UK Ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Tetris Pharma Lts shared | £304,504,000 | 23 Apr 2023 | active |
| Teva UK Limited shared | £304,504,000 | 23 Apr 2023 | active |
| Theramex HQ UK shared | £304,504,000 | 23 Apr 2023 | active |
| Tillomed Laboratories ltd shared | £304,504,000 | 23 Apr 2023 | active |
| Wockhardt UK Limited shared | £304,504,000 | 23 Apr 2023 | active |
| Xiromed shared | £304,504,000 | 23 Apr 2023 | active |
| Zentiva Pharma UK Ltd shared | £304,504,000 | 23 Apr 2023 | active |
description
NHS Framework Agreement for Branded Medicines - National Proprietary Pharmaceuticals
Offer reference number: CM/PHR/22/5675
CM/PHR/22/5675/01 - NHS Framework Agreement for Branded Medicines - National Category Tender Lot 1. Period of framework: 1 May 2023 to 30 April 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months
CM/PHR/22/5675/02 - NHS Framework Agreement for Branded Medicines - National Tender Lot 2. Period of framework: 1 May 2023 to 30 April 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 6 Apr 2023 | Award (award) | · | 4df14586-94d9-4b98-adbf-f5a321e30282-633180 |
more from NHS England
- Urgent Award - haematological screening · £16,202 · 29 Jul 2026
- HSCN-AWS Connectivity Service for Spine · £228,060 · 29 Jul 2026
- Incentive Voucher Provider · £60,000 · 29 Jul 2026
- CRM for NHSE participant/candidate data 26-27 · £56,640 · 28 Jul 2026
- Wayfinder and First Contact Digital Clinical Support 2026-27 · £748,000 · 23 Jul 2026
- Support Services for PPM application · £860,000 · 22 Jul 2026
- Digital Maturity Assessment · 21 Jul 2026
- Integrated Healthcare Services to Haslar Immigration Removal Centre (IRC) · £19,052,186 · 13 Jul 2026
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.